First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. This study aimed to compare the treatment respon...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2022-09-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/7069 |
| _version_ | 1827317517405650944 |
|---|---|
| author | Selin Aktürk Esen Yakup Ergun Cihan Erol Rukiye Arikan Muhammed Muhiddin Er Muhammed Mustafa Atci Atakan Topçu Gökhan Uçar Baran Akagündüz Musa Bariş Aykan Miraç Özen Naziyet Köse Baytemur Melike Özçelik Elif Şahin Denizcan Güven Serkan Menekşe Naziye Ak Fatih Teker Engin Kut Teoman Şakalar Özkan Alan Turgut Kaçan Nazim Serdar Turhal Saadettin Kiliçkap Sema Türker Mehmet Ali Nahit Şendur Osman Köstek Mustafa Karaağaç Abdullah Sakin Haci Mehmet Türk Dilek Çağlayan Şener Cihan Yusuf Açikgöz Doğan Uncu |
| author_facet | Selin Aktürk Esen Yakup Ergun Cihan Erol Rukiye Arikan Muhammed Muhiddin Er Muhammed Mustafa Atci Atakan Topçu Gökhan Uçar Baran Akagündüz Musa Bariş Aykan Miraç Özen Naziyet Köse Baytemur Melike Özçelik Elif Şahin Denizcan Güven Serkan Menekşe Naziye Ak Fatih Teker Engin Kut Teoman Şakalar Özkan Alan Turgut Kaçan Nazim Serdar Turhal Saadettin Kiliçkap Sema Türker Mehmet Ali Nahit Şendur Osman Köstek Mustafa Karaağaç Abdullah Sakin Haci Mehmet Türk Dilek Çağlayan Şener Cihan Yusuf Açikgöz Doğan Uncu |
| author_sort | Selin Aktürk Esen |
| collection | DOAJ |
| description |
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. This study aimed to compare the treatment response and survival characteristics of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer who received fluorouracil, oxaliplatin, and leucovorin (mFOLFOX)+trastuzumab or cisplatin and fluorouracil (CF)+trastuzumab as first-line therapy. It was a multicenter, retrospective study of the Turkish Oncology Group, which included 243 patients from 21 oncology centers. There were 113 patients in the mFOLFOX+trastuzumab arm and 130 patients in the CF+trastuzumab arm. The median age was 62 years in the mFOLFOX+trastuzumab arm and 61 years in the CF+trastuzumab arm (P = 0.495). 81.4% of patients in the mFOLFOX+trastuzumab arm and 83.1% in the CF+trastuzumab arm had gastric tumor localization (P = 0.735). The median progression-free survival (PFS) was significantly higher in the mFOLFOX+trastuzumab arm (9.4 months vs. 7.3 months, P = 0.024). The median overall survival (OS) was similar in both groups (18.4 months vs. 15.1 months, P = 0.640). Maintenance trastuzumab was continued after chemotherapy in 101 patients. In this subgroup, the median OS was 23.3 months and the median PFS was 13.3 months. In conclusion, mFOLFOX+trastuzumab is similar to CF+trastuzumab in terms of the median OS, but it is more effective in terms of the median PFS in the first-line treatment of HER2-positive metastatic gastric and GEJ cancer. The choice of treatment should be made by considering the prominent toxicity findings of the chemotherapy regimens.
|
| first_indexed | 2024-04-24T23:39:04Z |
| format | Article |
| id | doaj.art-76c42bc31695447ca49b70652deb5b62 |
| institution | Directory Open Access Journal |
| issn | 2831-0896 2831-090X |
| language | English |
| last_indexed | 2024-04-24T23:39:04Z |
| publishDate | 2022-09-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj.art-76c42bc31695447ca49b70652deb5b622024-03-15T13:30:58ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2022-09-0122510.17305/bjbms.2021.7069First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancerSelin Aktürk Esen0Yakup Ergun1https://orcid.org/0000-0003-4784-6743Cihan Erol2https://orcid.org/0000-0003-3155-8798Rukiye Arikan3https://orcid.org/0000-0003-2688-1515Muhammed Muhiddin Er4https://orcid.org/0000-0002-0583-0295Muhammed Mustafa Atci5Atakan Topçu6https://orcid.org/0000-0002-3634-4820Gökhan Uçar7https://orcid.org/0000-0002-7649-1075Baran Akagündüz8Musa Bariş Aykan9https://orcid.org/0000-0001-7538-9119Miraç Özen10https://orcid.org/0000-0002-1934-0190Naziyet Köse Baytemur11https://orcid.org/0000-0002-3587-2517Melike Özçelik12https://orcid.org/0000-0003-0406-715XElif Şahin 13https://orcid.org/0000-0002-1976-3951Denizcan Güven 14https://orcid.org/0000-0002-6924-9467Serkan Menekşe15https://orcid.org/0000-0002-2134-2128Naziye Ak16https://orcid.org/0000-0001-5790-7066Fatih Teker17Engin Kut18https://orcid.org/0000-0002-5328-5607Teoman Şakalar19https://orcid.org/0000-0003-2749-9414Özkan Alan20https://orcid.org/0000-0002-6635-2012Turgut Kaçan 21Nazim Serdar Turhal22https://orcid.org/0000-0002-1013-5676Saadettin Kiliçkap23https://orcid.org/0000-0003-1637-7390Sema Türker 24https://orcid.org/0000-0001-9040-7266Mehmet Ali Nahit Şendur25https://orcid.org/0000-0001-7021-6139Osman Köstek26https://orcid.org/0000-0002-1901-5603Mustafa Karaağaç 27https://orcid.org/0000-0003-4533-0620Abdullah Sakin 28https://orcid.org/0000-0003-2538-8569Haci Mehmet Türk29https://orcid.org/0000-0003-2206-8148Dilek Çağlayan 30https://orcid.org/0000-0003-4629-6815Şener Cihan31Yusuf Açikgöz 32https://orcid.org/0000-0002-0360-7938Doğan Uncu 33https://orcid.org/0000-0002-0929-3271Department of Medical Oncology, Ankara City Hospital, Ankara, TurkeyDepartment of Medical Oncology, Batman Training And Research Hospital, Batman, TurkeyDepartment of Medical Oncology, Ankara City Hospital, Ankara, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, TurkeyDepartment of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, TurkeyDepartment of Medical Oncology, Prof. Dr. Cemil Taşcioğlu City Hospital, Istanbul, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University Istanbul, TurkeyDepartment of Medical Oncology, Ankara City Hospital, Ankara, TurkeyDepartment of Medical Oncology, Erzincan Binali Yildirim University, Erzincan, TurkeyDepartment of Medical Oncology, Gulhane Medical Faculty, Health Sciences University, Ankara, Turkey Department of Medical Oncology, Faculty of Medicine, Sakarya University Sakarya, TurkeyDepartment of Medical Oncology, Memorial Ankara Hospital, Ankara, TurkeyDepartment of Medical Oncology, Ümraniye Training And Research Hospital, İstanbul, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, TurkeyDepartment of Medical Oncology, Manisa City Hospital, Manisa, TurkeyDepartment of Medical Oncology, Yozgat City Hospital, Yozgat, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, TurkeyDepartment of Medical Oncology, Manisa City Hospital, Manisa, TurkeyDepartment of Medical Oncology, Kahramanmaraş Necip Fazil City Hospital, Kahramanmaraş, TurkeyDepartment of Medical Oncology, Tekirdağ İsmail Fehmi Cumalioğlu City Hospital, Tekirdağ, TurkeyDepartment of Medical Oncology, Yüksek İhtisas Training And Research Hospital, Health Sciences University Bursa, Bursa, TurkeyDepartment of Medical Oncology, Anadolu Health Center, İstanbul, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, TurkeyDepartment of Medical Oncology, Zonguldak Atatürk State Hospital, Zonguldak, TurkeyDepartment of Medical Oncology, Ankara City Hospital, Ankara, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, TurkeyDepartment of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, TurkeyDepartment of Medical Oncology, Prof. Dr. Cemil Taşcioğlu City Hospital, Istanbul, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University Istanbul, TurkeyDepartment of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, TurkeyDepartment of Medical Oncology, Prof. Dr. Cemil Taşcioğlu City Hospital, Istanbul, TurkeyDepartment of Medical Oncology, Ankara City Hospital, Ankara, TurkeyDepartment of Medical Oncology, Ankara City Hospital, Ankara, Turkey Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. This study aimed to compare the treatment response and survival characteristics of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer who received fluorouracil, oxaliplatin, and leucovorin (mFOLFOX)+trastuzumab or cisplatin and fluorouracil (CF)+trastuzumab as first-line therapy. It was a multicenter, retrospective study of the Turkish Oncology Group, which included 243 patients from 21 oncology centers. There were 113 patients in the mFOLFOX+trastuzumab arm and 130 patients in the CF+trastuzumab arm. The median age was 62 years in the mFOLFOX+trastuzumab arm and 61 years in the CF+trastuzumab arm (P = 0.495). 81.4% of patients in the mFOLFOX+trastuzumab arm and 83.1% in the CF+trastuzumab arm had gastric tumor localization (P = 0.735). The median progression-free survival (PFS) was significantly higher in the mFOLFOX+trastuzumab arm (9.4 months vs. 7.3 months, P = 0.024). The median overall survival (OS) was similar in both groups (18.4 months vs. 15.1 months, P = 0.640). Maintenance trastuzumab was continued after chemotherapy in 101 patients. In this subgroup, the median OS was 23.3 months and the median PFS was 13.3 months. In conclusion, mFOLFOX+trastuzumab is similar to CF+trastuzumab in terms of the median OS, but it is more effective in terms of the median PFS in the first-line treatment of HER2-positive metastatic gastric and GEJ cancer. The choice of treatment should be made by considering the prominent toxicity findings of the chemotherapy regimens. https://www.bjbms.org/ojs/index.php/bjbms/article/view/7069CFFOLFOXgastric cancergastroesophageal junction cancertrastuzumab |
| spellingShingle | Selin Aktürk Esen Yakup Ergun Cihan Erol Rukiye Arikan Muhammed Muhiddin Er Muhammed Mustafa Atci Atakan Topçu Gökhan Uçar Baran Akagündüz Musa Bariş Aykan Miraç Özen Naziyet Köse Baytemur Melike Özçelik Elif Şahin Denizcan Güven Serkan Menekşe Naziye Ak Fatih Teker Engin Kut Teoman Şakalar Özkan Alan Turgut Kaçan Nazim Serdar Turhal Saadettin Kiliçkap Sema Türker Mehmet Ali Nahit Şendur Osman Köstek Mustafa Karaağaç Abdullah Sakin Haci Mehmet Türk Dilek Çağlayan Şener Cihan Yusuf Açikgöz Doğan Uncu First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer Biomolecules & Biomedicine CF FOLFOX gastric cancer gastroesophageal junction cancer trastuzumab |
| title | First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer |
| title_full | First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer |
| title_fullStr | First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer |
| title_full_unstemmed | First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer |
| title_short | First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer |
| title_sort | first line treatment of patients with her2 positive metastatic gastric and gastroesophageal junction cancer |
| topic | CF FOLFOX gastric cancer gastroesophageal junction cancer trastuzumab |
| url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/7069 |
| work_keys_str_mv | AT selinakturkesen firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT yakupergun firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT cihanerol firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT rukiyearikan firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT muhammedmuhiddiner firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT muhammedmustafaatci firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT atakantopcu firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT gokhanucar firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT baranakagunduz firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT musabarisaykan firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT miracozen firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT naziyetkosebaytemur firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT melikeozcelik firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT elifsahin firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT denizcanguven firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT serkanmenekse firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT naziyeak firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT fatihteker firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT enginkut firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT teomansakalar firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT ozkanalan firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT turgutkacan firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT nazimserdarturhal firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT saadettinkilickap firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT sematurker firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT mehmetalinahitsendur firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT osmankostek firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT mustafakaraagac firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT abdullahsakin firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT hacimehmetturk firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT dilekcaglayan firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT senercihan firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT yusufacikgoz firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer AT doganuncu firstlinetreatmentofpatientswithher2positivemetastaticgastricandgastroesophagealjunctioncancer |